The Use of the Functional Movement Screen™ in Preventing Injuries in Amateur Rugby Players
NCT ID: NCT06715618
Last Updated: 2024-12-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
40 participants
OBSERVATIONAL
2024-10-03
2025-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The implementation of a risk prevention tool is particularly relevant for a population prone to injuries. However, the practicality of such a tool must be considered, as adherence to an injury prevention program depends on the "perceived usefulness, intensity, and time investment of the program".
One tool appears to meet these criteria: the Functional Movement Screen™ (FMS™). This tool is designed to "evaluate an individual's functional movement patterns" and, according to its authors, can serve as "a crucial tool" for returning to sports after an injury or a period of inactivity. Given the high incidence of injuries in rugby players, calculating the injury incidence in this population and correlating it with FMS™ scores could provide valuable insights.
For this prospective study, forty amateur rugby players from various clubs in Normandy competing at the Federal 3 level will be recruited using a recruitment letter and a call for volunteers.
Each participant will perform two FMS™ (7 movements), at the beginning of the competitive season and at the end of the competitive season. The test will last 30 minutes per player. The initial interview will last 20 minutes. There will also be a follow-up of the players throughout the season to collect all injuries sustained by participants in the intervention.
The main expected outcome is a significant correlation (p \< 0.05) between the FMS™ score and injury incidence. This correlation may then indicate a good predictive capacity of the FMS™, allowing it to be considered a predictive tool for injury risk.
To evaluate the correlation between two variables (injury incidence sustained by the player and the FMS™ score), the Spearman correlation coefficient will be used. This coefficient, if its value approaches -1 or 1, will indicate a good correlation between the player's injury incidence and their FMS™ score. Conversely, if the coefficient approaches 0, the correlation will be considered poor.
In a second phase, it is expected that a competitive season will directly affect the FMS™ score, highlighting the difficulty for an amateur player to maintain their physical capacities throughout an entire season.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
FMS group
Each participant will perform two FMS™, one at the beginning of the competitive season and one at the end of the competitive season. The test will take 30 minutes per player. The initial interview will last 20 minutes. Players will also be monitored throughout the season to collect all injuries sustained by the participants in the study.
FMS test
Each participant will perform two FMS™, one at the beginning of the competitive season and one at the end of the competitive season. The test will take 30 minutes per player. The initial interview will last 20 minutes. Players will also be monitored throughout the season to collect all injuries sustained by the participants in the study.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
FMS test
Each participant will perform two FMS™, one at the beginning of the competitive season and one at the end of the competitive season. The test will take 30 minutes per player. The initial interview will last 20 minutes. Players will also be monitored throughout the season to collect all injuries sustained by the participants in the study.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Players aged at least 18 years old, legally adults.
* Healthy players who have not sustained any musculoskeletal injuries or undergone surgical interventions in the past 6 months.
* Players competing in "Fédérale 3."
* Players from clubs based in Normandy.
Exclusion Criteria
* Female players
* Players injured during the first interview or the first FMS™
* Players who are or have been professional athletes
* Players with a history of frequent serious injuries that could pose a risk to their continued participation
18 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hopital La Musse
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hôpital La Musse
Saint-Sébastien-de-Morsent, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Héloïse BAILLET, PhD
Role: primary
Héloïse BAILLET, PhD
Role: backup
Bastien AGULLO
Role: backup
Charlotte MENEZ, PhD
Role: backup
Lucas BOCENO
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2024-A01804-43
Identifier Type: -
Identifier Source: org_study_id